ICRA has assigned A1+ indicating the highest credit quality to short term debt instruments and LAA- indicating high credit quality to long term debt instruments rating to the Rs. 200 million fund based and non-fund based limits of Transasia Bio-Medicals Limited.The assigned ratings take into account Transasia’s leadership position in the domestic IVD market with strong promoter background and management expertise. Transasia has pan India marketing and distribution network with strong focus on after sales service which is a source of competitive advantage. The company has exclusive tie-ups with international players like Sysmex, Diesse, Medica for advanced IVD equipment and caters to all segments comprising of private hospitals and labs, public hospitals and Government owned entities. The financial risk profile of the company is very strong with relatively higher profitability and return on capital employed. The company is debt free and has strong liquidity in the form of investments generated out of past profits.
- NEWS REVIEW – WORLD
- iSOFT wins major projects in Spain